4basebio (4BB)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

1,155.00p
   
  • Change Today:
      35.00p
  • 52 Week High: 1,820.00
  • 52 Week Low: 950.00
  • Currency: UK Pounds
  • Shares Issued: 15.50m
  • Volume: 2,420
  • Market Cap: £178.98m
  • Beta: 0.02

Deal with Barclays    Trade now with Barclays Stockbrokers

4basebio Overview

4basebio UK Societas ("4bb" or "the Company") is a specialist life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for effective and safe delivery of these DNA based products to patients. Its main country of operation is the UK. It is the intention of the Company to become a market leader in the manufacture and supply of high purity, synthetic DNA for research, therapeutic and pharmacological use. The principal objective of 4bb is to validate and scale its DNA synthesis process with a view to manufacturing Good Manufacturing Practice ("GMP") grade DNA, suitable for use in gene therapies and DNA vaccines.

Key Personnel

CEO: Heikki Lanckriet
CFO: David John Roth
Chief Operating Officer: Amy Walker
Independent Non-Executive Director: Alan Malus
Independent Non-Executive Director: Maria Del Pilar de la Huerta
Non-Executive Chairman: Timothy Paul McCarthy
Non-Executive Dir: Hansjörg Plaggemars, Joseph Manuel Fernández

Contact Details

Address: 25 Norman Way, Over, Cambridge, United Kingdom, CB24 5QE
Phone: +44 (0)1223 967943
Website: http://www.4basebio.com/

Listings

Sector: Pharma and Biotech(LSE)
Index: FTSE AIM All-Share
ISIN: GB00BMCLYF79

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

4basebio Market Data

Currency UK Pounds
Share Price 1,155.00p
Change Today 35.00p
% Change 3.13 %
52 Week High 1,820.00
52 Week Low 950.00
Volume 2,420
Shares Issued 15.50m
Market Cap £178.98m
Beta 0.02

4basebio Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
21.99% below the market average21.99% below the market average21.99% below the market average21.99% below the market average21.99% below the market average
23.40% above the sector average23.40% above the sector average23.40% above the sector average23.40% above the sector average23.40% above the sector average
Price Trend
62.09% above the market average62.09% above the market average62.09% above the market average62.09% above the market average62.09% above the market average
70.83% above the sector average70.83% above the sector average70.83% above the sector average70.83% above the sector average70.83% above the sector average
Income Not Available
Growth
38.10% above the market average38.10% above the market average38.10% above the market average38.10% above the market average38.10% above the market average
29.03% above the sector average29.03% above the sector average29.03% above the sector average29.03% above the sector average29.03% above the sector average

4basebio Dividends

No dividends found

Trades for 11-Apr-2025

Time Volume / Share Price
15:28 1,500 @ 1,150.00p

4basebio Key Personnel

CEO Heikki Lanckriet
CFO David John Roth

Top of Page